Mariana Leão

Mariana Leão

Auto-generated profile, based on publicly available information

Mariana Leão

UCIBIO/REQUIMTE, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n.° 164, 4050-313 Porto, Portugal; Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n.° 164, 4050-313, Porto, Portugal

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Biochemical Pharmacology
Verified
Journal Article
Closed access
MLMariana Leão
Mariana Leão
Clara PereiraClara Pereira
Clara Pereira
ABAlessandra BISIO
Alessandra BISIO
Yari CiribilliYari Ciribilli
Yari Ciribilli
APAna M. Paiva
Ana M. Paiva
Lucília SaraivaLucília Saraiva
Lucília Saraiva

1 January 2012 in Journal of Biomedicine and Biotechnology
Verified
Journal Article
Open access
PDF file
Clara PereiraClara Pereira
Clara Pereira
CBCláudia Bessa
Cláudia Bessa
JSJoana Soares
Joana Soares
MLMariana Leão
Mariana Leão
Lucília SaraivaLucília Saraiva
Lucília Saraiva
As a model organismSaccharomyces cerevisiaehas greatly contributed to our understanding of many fundamental aspects of cellular biology in higher eukaryotes. More recently, engineered yeast models developed to study endogenous or heterologous proteins that lay at the root of a given disease have become powerful tools for unraveling the molecular basis of complex human diseases like neurodegeneration. Additionally, with the possibility of performing target-directed large-scale screenings, yeast models have emerged as promising first-line approaches in the discovery process of novel therapeutic opportunities against these pathologies. In this paper, several yeast models that have contributed to the uncovering of the etiology and pathogenesis of several neurodegenerative diseases are described, including the most common forms of neurodegeneration worldwide, Alzheimer's, Parkinson's, and Huntington's diseases. Moreover, the potential input of these cell systems in the development of more effective therapies in neurodegeneration, through the identification of genetic and chemical suppressors, is also addressed.

1 May 2015 in Pharmacological Research
Verified
Journal Article
Closed access
JSJoana Soares
Joana Soares
LRLiliana Raimundo
Liliana Raimundo
NPNuno A.L. Pereira
Nuno A.L. Pereira
Daniel J. V. A. dos SantosDaniel J. V. A. dos Santos
Daniel J. V. A. dos Santos
Maria PerezMaria Perez
Maria Perez
Lucília SaraivaLucília Saraiva
Lucília Saraiva

10 February 2012 in The FEBS Journal
Verified
Journal Article
Closed access
PDF file
Clara PereiraClara Pereira
Clara Pereira
ICIsabel Coutinho
Isabel Coutinho
JSJoana Soares
Joana Soares
CBCláudia Bessa
Cláudia Bessa
MLMariana Leão
Mariana Leão
Lucília SaraivaLucília Saraiva
Lucília Saraiva

1 September 2012 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
Clara PereiraClara Pereira
Clara Pereira
MLMariana Leao
Mariana Leao
JSJoana Soares
Joana Soares
CBCláudia Bessa
Cláudia Bessa
Lucília SaraivaLucília Saraiva
Lucília Saraiva
Despite great advances in understanding the molecular etiology of cancer and neurodegeneration, therapeutic strategies against these diseases are still largely lacking. Hence, acceleration of the discovery of new therapeutic agents against these pathologies is of enormous interest. This review is focused on the role of multi-faceted and expanding yeast cell-based systems in the search for new drugs and therapeutic targets in cancer and neurodegeneration. Though the obvious limitations of using a microorganism to address human diseases, when used in the early phase and with complementary mammalian systems, it can have a tremendous impact in the discovery of new therapeutic opportunities. In this review, many evidence are provided demonstrating the valuable contribution of yeast in this area. Additionally, several yeast target-based drug screening approaches based on a readily screenable phenotype on genomic technologies increasingly oriented towards genetic and chemical high-throughput analysis are addressed. Altogether, with this review, we intend not only to recognize previous successes and ongoing work in this area, but also to point out new opportunities that may be of interest for yeast as a model organism and as a powerful system in the discovery of new lead compounds that have the potential to become novel drugs in cancer and neurodegeneration.

17 October 2009 in FEBS Letters
Verified
Journal Article
Closed access
ICIsabel Coutinho
Isabel Coutinho
GPGil Pereira
Gil Pereira
MLMariana Leão
Mariana Leão
Jorge GonçalvesJorge Gonçalves
Jorge Gonçalves
MCManuela Côrte-Real
Manuela Côrte-Real
Lucília SaraivaLucília Saraiva
Lucília Saraiva